睿知中国医院研究地图
候选清单

即将招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由中山大学孙逸仙纪念医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07630103,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:仅女性

    登记记录的入选字段

  2. Histologically or cytologically confirmed HER2-positive (IHC 3+ and/or ISH positive) unresectable or metastatic breast cancer.

    入选标准第 2 条

  3. Prior treatment with trastuzumab and a taxane in the recurrent or metastatic setting. Or recurrence during or within 12 months (disease-free interval, DFI) after completing neoadjuvant/adjuvant chemotherapy and/or anti-HER2 targeted therapy.

    入选标准第 3 条

    Toxicities from prior anti-tumor therapy that have not recovered to ≤ Grade 1 (according to NCI-CTCAE v6.0).

    排除标准第 11 条

  4. ECOG Performance Status of 0 or 1.

    入选标准第 5 条

  5. At least one measurable lesion according to RECIST v1.1 criteria.

    入选标准第 6 条

  6. History of other malignancies within the past 5 years, excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.

    排除标准第 2 条

    Having undergone major cancer-related surgery, radiotherapy, chemotherapy, immunotherapy, molecular targeted therapy, biotherapy, or other clinical investigational therapy within 4 weeks prior to the first dose.

    排除标准第 4 条

    History of immunodeficiency, including a positive HIV test, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.

    排除标准第 8 条

  7. Female subjects of childbearing potential must have a negative pregnancy test at screening and must agree to use highly effective contraception methods from the signing of the informed consent form until 7 months after the last dose of the investigational product.

    入选标准第 8 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07630103,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Female patients aged ≥18 and ≤75 years.
  2. Histologically or cytologically confirmed HER2-positive (IHC 3+ and/or ISH positive) unresectable or metastatic breast cancer.
  3. Prior treatment with trastuzumab and a taxane in the recurrent or metastatic setting. Or recurrence during or within 12 months (disease-free interval, DFI) after completing neoadjuvant/adjuvant chemotherapy and/or anti-HER2 targeted therapy.
  4. Documented radiological disease progression (during or after the most recent prior therapy).
  5. ECOG Performance Status of 0 or 1.
  6. At least one measurable lesion according to RECIST v1.1 criteria.
  7. Adequate organ function meeting the following criteria (without the use of any blood components, cytokines, or growth factors for correction within 14 days prior to the first dose):
  8. Female subjects of childbearing potential must have a negative pregnancy test at screening and must agree to use highly effective contraception methods from the signing of the informed consent form until 7 months after the last dose of the investigational product.
  9. Willing and able to provide written informed consent, with good compliance, and willing to cooperate with follow-up visits and study-related procedures.

排除标准:Exclusion Criteria:

  1. Patients with known untreated spinal cord compression or active central nervous system (CNS) metastases, except for those who have been treated and have remained stable for at least 1 month and have discontinued corticosteroids for >2 weeks.
  2. History of other malignancies within the past 5 years, excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.
  3. Uncontrolled third-space fluid accumulation (e.g., massive ascites, pleural effusion, pericardial effusion) that cannot be managed by drainage or other methods.
  4. Having undergone major cancer-related surgery, radiotherapy, chemotherapy, immunotherapy, molecular targeted therapy, biotherapy, or other clinical investigational therapy within 4 weeks prior to the first dose.
  5. Prior treatment with an antibody-drug conjugate containing an exatecan derivative (a topoisomerase I inhibitor).
  6. Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes (at doses >10 mg/day prednisone or equivalent) within 2 weeks prior to the first dose, excluding topical, nasal spray, or inhaled corticosteroids.
  7. Presence of any active autoimmune disease or a history of autoimmune disease that may potentially recur.
  8. History of immunodeficiency, including a positive HIV test, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
  9. Patients with known or suspected interstitial lung disease (ILD); or presence of other moderate-to-severe pulmonary diseases that may significantly impair respiratory function or interfere with the detection or management of drug-related pulmonary toxicity within 3 months prior to the first dose, including but not limited to idiopathic pulmonary fibrosis, organizing pneumonia/bronchiolitis obliterans, pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease (COPD), obstructive/restrictive lung disease, etc.; and any autoimmune, connective tissue, or inflammatory disorders involving the lungs, such as rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc.; or history of pneumonectomy. Patients who experienced ≥Grade 3 ILD during prior treatment with immune checkpoint inhibitors are excluded.
  10. Presence of active hepatitis B (HBsAg positive and HBV DNA ≥500 IU/mL), hepatitis C (anti-HCV positive and HCV RNA above the upper limit of normal), or liver cirrhosis; or severe infections requiring systemic antibiotic, antiviral, or antifungal therapy.
  11. Toxicities from prior anti-tumor therapy that have not recovered to ≤ Grade 1 (according to NCI-CTCAE v6.0).
  12. Known hypersensitivity to any of the study drugs or their excipients.
  13. Any other severe physical or mental illness or abnormal laboratory finding that, in the investigator's judgment, may increase the risk associated with study participation, interfere with the study results, or make the patient unsuitable for participation in this study.

引自 ClinicalTrials.gov, NCT07630103, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07630103,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07630103